Allakos Inc ALLK

Healthcare Biotechnology

Allakos Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis, eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is conducting pre-clinical studies with AK007, which is designed to block known ligand interaction with Siglec-10. It is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

NDAQ:ALLK - Post by User

Allakos Inc

Bullboard Posts

(4)
•••

Post by AviseAnalyticson Jan 10, 2022 7:47am

194 Views

Post# 34299064

SHOULD ALLAKOS INC BE ON YOUR INVESTMENT WATCHLIST?

$ALLK

Allakos Inc. (NASDAQ:ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for treatment of inflammatory, and proliferative diseases, faced a setback with disappointing results from a crucial phase 3 trial named Enigma 2 and phase 2/3 Kryptos trial.

Should you invest in the Company or watch from the sidelines?

Read on to find out more!

https://www.aviseanalytics.com/should-allakos-inc-be-on-your-investment-watchlist/

Bullboard Posts

This stock is ready to capture the lead in the diabetes market